ArticleHeliyon2019
Evaluation of crystal violet decolorization assay and resazurin microplate assay for antimycobacterial screening.
Article in Heliyon, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Water-soluble triazole-based azo-Schiff base fluorescent-colorimetric dual chemosensor for selective detection of sulfide ions: analytical and biological applications.RSC advances · 2026Article
- Tuning the hydrophobicity of glycine ester throughRSC advances · 2026Article
- Development of Resazurin-Based Assay for Rapid Evaluation of Sodium Hypochlorite Tolerance inFoods (Basel, Switzerland) · 2026Article
- Regulatory mechanism of cholesterol transport via LtmA in Mycobacterium smegmatis.Scientific reports · 2026Article
- In vitro and in silico evaluation of phytocompounds from Leucaena leucocephala and Entada phaseoloides targeting DNA gyrase, topoisomerase II, AKT1.Scientific reports · 2025Article
- Integration of AI and ML in Tuberculosis (TB) Management: From Diagnosis to Drug Discovery.Diseases (Basel, Switzerland) · 2025Review
- Insights into the in-vitro Susceptibility and Drug-Drug Interaction Profiles Against Drug-Resistant and SusceptibleInfection and drug resistance · 2024Article
- Antimicrobial, Antibiofilm, and Anticancer Activities ofMolecules (Basel, Switzerland) · 2023Article
- The Effect of Inoculum Size on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis.Microbiology spectrum · 2023Article
- Article
- Antibiotic Susceptibility of Mycobacteria Isolated from Ornamental Fish.Journal of veterinary research · 2022Article
- Potential secondary metabolite from Indonesian Actinobacteria (InaCC A758) againstIranian journal of basic medical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main obstacle in antimycobacterial discovery is the extremely slow growth rates of pathogenic mycobacteria that lead to the long incubation times needed in antimycobacterial screening. Some
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.